Affective Disorders: Neurobiology and Treatment

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

34 Terms

1
New cards

What is the Aetiology of Depression?

  1. Multifactorial

  2. Incompletely understood

  3. Interactions of: genetic factors, personality, early environment, childhood adversities, life events, psychological predisposition and biological factors


2
New cards

Complex and Multifactorial Aetiology

knowt flashcard image


3
New cards

What are the Genetic Causes of Depression?

  1. The risk of depression in 1st  relatives of a proband is approx. 3-fold increased

  2. The heritability of major depression has been estimated at 37%, less than that of bipolar disorder or schizophrenia

  3. Genome-wide association studies now identify hundreds of risk variants (697 in Adams et al., Cell 2025), each of very small effect

  4. Polygenic inheritance: genetic liability results from the combined action of many genes of small effect, in interaction with the environment


4
New cards

What is the Neurobiology of Depression?

  1. Dysfunction  of neural circuitries involved in mood regulation

  2. Abnormal monoamine systems

  3. Gaba, Glutamate and excitatory-inhibitory balance

  4. HPA Axis, Glucocorticoids and stress biology

  5. Neuroplasticity, synapses loss and brain atrophy

  6. Immune-brain interactions


5
New cards

Neural Circuitries in Depression

knowt flashcard image


6
New cards

What are the Serotonin and Noradrenaline Pathways in the Human Brain?

knowt flashcard image


7
New cards

Serotonin (5HT) Dysfunction in Depression

  1. All traditional antidepressants act on 5-HT/NA systems (indirect evidence, inferred from drug action)

  2. Relapse after experimentally lowering brain 5-HT (acute tryptophan depletion) in recovered patients

  3. Reduced 5-HT transporter in post-mortem suicide studies

  4. Reduced brain 5-HT release in depressed patients (PET; Erritzoe et al., 2023)

  5. 'low serotonin’ is not a single cause of depression; serotonin is one part of a more complex picture


8
New cards

HPA Dysfunction in Depression

knowt flashcard image


9
New cards

Neuroplasticity Alterations and Subcortical Atrophy

knowt flashcard image


10
New cards

Ketamine in Depression

knowt flashcard image


11
New cards

Immune-Brain Interaction in Depression


12
New cards

Bipolar Disorder- Genetic Causes

  1. Familial aggregation: about 5–10% risk in first-degree relatives (roughly 7–10 times the population risk)

  2. Heritability 60–85% (twin studies)

  3. Polygenic inheritance: thousands of genetic variants of small effect

  4. GWAS: 298 risk loci (O’Connell et al., Nature 2025), including CACNA1C (L-type calcium channel subunit), a well-replicated finding

  5. Genetic overlap with schizophrenia is greater than with depression


13
New cards

Bipolar Disorder- Role of Environment

  1. Monozygotic twins concordance rate around 60%—>environmental factors likely to be important

  2. Stressful life events or sleep disturbance can trigger episodes

  3. Life trauma increases the risk of bipolar disorder (as of any other psychiatric disorder), i.e. it seems non-specific


14
New cards

What is Neurobiology of Bipolar Disorder?

  1. Neurochemistry (excessive dopamine in mania, and 5HT abnormalities in depression)

  2. HPA Axis and cortisol

  3. Neuroprogression (in a subset of patients)

  4. (Neuro)metabolic and mitochondrial abnormalities


15
New cards

Dopamine and Neuroprogression in Bipolar Disorder

knowt flashcard image


16
New cards

What is the Bidirectional Relationship Between Metabolic Dysregulation and Bipolar Disorder?

knowt flashcard image


17
New cards

Depression Treatment- Types and Phases

knowt flashcard image


18
New cards

Antidepressants- 1st Generation (Non-Selective)

knowt flashcard image


19
New cards

Antidepressants- 2nd Generation

2nd generation

  1. SSRIs – selective serotonin reuptake inhibitors (sertraline, citalopram, escitalopram, fluoxetine, paroxetine)

  2. SNRIs – serotonin–noradrenaline reuptake inhibitors (venlafaxine, duloxetine)

  3. Mirtazapine – α2-adrenoceptor antagonist (↑ NA and 5-HT release); also blocks 5-HT2, 5-HT3 and H1 receptors

  4. Vortioxetine – multimodal: serotonin reuptake inhibitor plus 5-HT receptor modulator

  5. Others: agomelatine, trazodone


20
New cards

How do Antidepressants Work?

Acute action (hours)

  1. SSRIs/SNRIs block the serotonin (SERT) and/or noradrenaline (NET) transporter → ↑ synaptic 5-HT/NA

  2. MAOIs block monoamine breakdown; TCAs block SERT/NET but also H1, muscarinic and α1 receptors (side effects)

  3. Mirtazapine blocks presynaptic α2 receptors → ↑ NA and 5-HT release


21
New cards

Why does Clinical Improvement take 2-6 Weeks?

  1. Raised 5-HT first activates inhibitory 5-HT1A autoreceptors on raphe neurons; these gradually desensitise → ↑ firing and release

  2. Downstream changes in gene expression, BDNF and synaptic plasticity

  3. An early shift towards positive emotional processing comes before mood improves (cognitive neuropsychological model; Harmer et al.)


22
New cards

Efficacy and Tolerability of SSRIs- Advantages

Advantages

  1. Efficacy equal to tricyclics in outpatients

  2. Large spectrum of action (OCD, PTSD, Panic, GAD, social anxiety)

  3. Low toxicity and safe in overdose


23
New cards

Efficacy and Tolerability of SSRIs- Side Effects

Side effects

  1. Initial treatment phase most delicate: side effects come before benefits

  2. Gastrointestinal symptoms (nausea, diarrhoea)

  3. Headache, irritability, anxiety

  4. Reduced libido and sexual dysfunction

  5. Taper gradually: withdrawal symptoms can be severe and prolonged in some people; worst with short half-life drugs (venlafaxine, paroxetine)


24
New cards

Antidepressant Safety- What to Watch For?

knowt flashcard image


25
New cards

Bipolar Disorder Treatment- Short-term

Short-term treatment

  • To reduce the severity and shorten the duration of the acute episode and achieve remission of symptoms


26
New cards

Bipolar Disorder Treatment- Long-term

Long-term treatment

  • Prevention of new episodes and to achieve adequate inter-episode control of residual or chronic mood symptoms


27
New cards

Bipolar Disorder Treatment- Overview of Drug Categories

knowt flashcard image


28
New cards

Lithium- Mechanism

  1. A simple element, also present in food and drinking water

  2. Mechanisms (incompletely understood)

  • Multiple intracellular second-messenger pathways (e.g. inositol depletion, GSK-3 inhibition)

  • Indirect effects on several neurotransmitter systems

  • Neurotrophic factors and cellular signalling


29
New cards

Lithium- Clinical Efficacy

Clinical efficacy

  1. Strongest evidence for preventing relapse of either polarity – first-line long-term treatment (NICE)

  2. Anti-suicidal effects and reduced impulsivity

  3. Possible neuroprotective effects


30
New cards

Lithium- Monitoring

Monitoring (NICE)

  1. Target level 0.6–0.8 mmol/L, 12 hours after the last dose

  2. Levels every 3 months for the first year, then every 6 months (every 3 months if older, interacting drugs, renal impairment or poor adherence)

  3. Renal and thyroid function, calcium and weight every 6 months

  4. Narrow therapeutic index: needs regular blood-level monitoring


31
New cards

Lithium- Toxicity

  1. Usually above 1.5 mmol/L, but can occur at 'therapeutic' levels

  2. Coarse tremor, vomiting, diarrhoea, ataxia, slurred speech, confusion, seizures

  3. Precipitated by dehydration, intercurrent illness, NSAIDs, ACE inhibitors/ARBs and thiazide diuretics


32
New cards

Lithium- Long-term Adverse Effects

Long-term adverse effects

  1. Reduced eGFR/chronic kidney disease, nephrogenic diabetes insipidus, hypothyroidism, hyperparathyroidism (raised calcium), weight gain


33
New cards

What are the Adverse Effects and Pharmacological Treatments for BPAD?

  1. Lithium toxicity – narrow therapeutic index; requires monitoring of plasma levels

  2. Kidney and thyroid dysfunction (lithium, especially with poorly controlled levels)

  3. Weight gain and metabolic syndrome (many second-generation antipsychotics, e.g. olanzapine and, to a lesser extent, quetiapine; valproate)

  4. Liver damage and pancreatitis (valproate)

  5. Serious skin rash, including Stevens–Johnson syndrome (lamotrigine – titrate slowly)

  6. Hyperprolactinaemia (dopamine antagonists)

  7. Tardive dyskinesia (much reduced risk with second-generation antipsychotics)

  8. Teratogenicity (valproate)


34
New cards

What are the Other Disadvantages of Pharmacological Treatments for BPAD?

  1. Stopping lithium abruptly can cause rebound mania

  2. Antidepressants can induce mania or rapid cycling

  3. Poor adherence and long-term engagement are common without psychoeducation and support for self-management

  4. Valproate in pregnancy: about 10% risk of major congenital malformations and 30–40% risk of neurodevelopmental disorders